tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TNF Pharma, DADA2 Foundation partner for isomyosamine compassionate use

TNF Pharmaceuticals (TNFA) announced it has formed a philanthropic collaboration with the DADA2 Foundation. The parties expect to initiate a Compassionate Use study evaluating TNF’s lead candidate isomyosamine as a potential treatment for DADA2, a rare pediatric autoinflammatory disease. TNF stated that its TNF-alpha inhibitor, isomyosamine, is an orally administered small molecule believed to be a potential superior alternative for treating DADA2.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1